UBS analyst A.J. Rice has maintained a Buy rating on PACS Group (NYSE: PACS) and raised the price target to $57. The previous target was $50. The revised target reflects increased confidence in the company's performance.

Rating and Price Target Details

The following table outlines the revised rating and price target for PACS Group:

The upgrade in the price target suggests a positive outlook for the stock.

PACS Group, Inc. shares climbed more than 7% on Tuesday after the company announced plans to expand its post-acute care portfolio through the acquisition of the operations of 34 skilled nursing facilities from Eduro Healthcare. The transaction will add 3,633 skilled nursing beds across six western states, significantly expanding PACS's footprint in the sector. The deal is expected to close in multiple tranches, with the majority of facilities anticipated to close in the third quarter of 2026, subject to regulatory approvals and other customary contingencies.

The portfolio is distributed across Texas with 22 facilities, Montana with six facilities, and South Dakota with three facilities. Additionally, one facility is located in each of New Mexico, North Dakota, and Utah. This move marks PACS's entry into four new states. Financial terms of the transaction were not disclosed.

Strategic Expansion and Operational Alignment

Jason Murray, PACS Chairman and CEO, emphasized the strategic value of the acquisition, noting the strong foundation of clinical care and operational performance established by Eduro. He stated that the company looks forward to building on the existing culture and success of these facilities. Josh Jergensen, PACS President and COO, highlighted the alignment between the operating models of both organizations, specifically their focus on empowering local leadership to deliver strong clinical and operational outcomes.

Technical Picture and Analyst Consensus

PACS continues to trade well above its 20-day, 50-day, 100-day and 200-day simple moving averages, signaling a strong long-term uptrend. The stock has also maintained a bullish "golden cross" since October 2025, with the 50-day moving average remaining above the 200-day moving average. Momentum indicators remain supportive, with the MACD sitting above its signal line and a positive histogram suggesting buying pressure is strengthening.

The stock carries a Strong Buy rating with an average price forecast of $49.00. Recent analyst moves include Truist Securities raising its forecast to $52.00 on May 18, Oppenheimer raising its forecast to $48.00 on May 13, and UBS raising its forecast to $44.00 on March 4.

Facility Breakdown

The following table details the distribution of the 34 facilities by state:

Seller Perspective

Mike Bewsey, Eduro’s Managing Director, expressed confidence in PACS as a partner that would embrace Eduro's culture and core values while providing continuity for employees. He noted that the transition follows two years of significant financial and clinical achievements for Eduro.